Tumor selective replication of Newcastle Disease Virus: Association with defects of tumor cells in antiviral defence

被引:112
作者
Fiola, Christoph
Peeters, Ben
Fournier, Philippe
Arnold, Annette
Bucur, Mariana
Schirrmacher, Volker
机构
[1] German Canc Res Ctr, Div Cellular Immunol, D-69120 Heidelberg, Germany
[2] Univ Wageningen & Res Ctr, Div Infect Dis, Anim Sci Grp, Lelystad, Netherlands
关键词
virus infection; tumor cells; antiviral proteins; interferon alpha; paramyxovirus;
D O I
10.1002/ijc.21821
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
To investigate tumor-selective viral replication, we compared several tumorigenic human cell lines to nontumorigenic human cells from the blood for the sensitivity to become infected by a recombinant lentogenic strain of Newcastle Disease Virus (NDV) with incorporated transgene EGFP (NDFL-EGFP). Although fluorescence signals in nontumorigenic cells were only weak or missing completely, a massive and long-lasting transgene-expression was observed in all tumor cell lines. The majority of tumor cells (50-95%) could be infected, and viral replication was associated with an increase in the cell surface density of viral antigens. To clarify the underlying mechanism of the observed difference in virus susceptibility we examined the kinetics of interferon-induced antiviral enzymes because NDV is a strong type-I interferon inducer. This analysis revealed several defects of tumor cells in their antiviral defence responses: They showed no response to UV-inactivated NDV, whereas nontumorigenic cells reacted with induction of high-levels of the antiviral enzymes PKR and MxA. Upon coincubation with live NDV, tumor cells showed a delayed response in the increased expression of the antiviral enzymes in comparison with PBMC. In nontumorigenic cells the replication cycle of NDV stopped after the production of positive-strand RNA, while tumor cells continued in the replication cycle and copied viral genomes 10-50 hr after infection. These results can explain the tumor selective replication behavior of this interesting antineoplastic virus. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:328 / 338
页数:11
相关论文
共 52 条
[1]
Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer [J].
Ahlert, T ;
Sauerbrei, W ;
Bastert, G ;
Ruhland, S ;
Bartik, B ;
Simiantonaki, N ;
Schumacher, J ;
Hacker, B ;
Schumacher, M ;
Schirrmacher, V .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1354-1366
[2]
Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[3]
Reovirus therapy of lymphoid malignancies [J].
Alain, T ;
Hirasawa, K ;
Pon, KJ ;
Nishikawa, SG ;
Urbanski, SJ ;
Auer, Y ;
Luider, J ;
Martin, A ;
Johnston, RN ;
Janowska-Wieczorek, A ;
Lee, PWK ;
Kossakowska, AE .
BLOOD, 2002, 100 (12) :4146-4153
[4]
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[5]
Gene encoding protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer [J].
Anand, N ;
Murthy, S ;
Amann, G ;
Wernick, M ;
Porter, LA ;
Cukier, IH ;
Collins, C ;
Gray, JW ;
Diebold, J ;
Demetrick, DJ ;
Lee, JM .
NATURE GENETICS, 2002, 31 (03) :301-305
[6]
Investigating the economic role of mergers [J].
Andrade, G ;
Stafford, E .
JOURNAL OF CORPORATE FINANCE, 2004, 10 (01) :1-36
[7]
[Anonymous], MONOGR VIROL
[8]
ASADA T, 1974, CANCER, V34, P1907, DOI 10.1002/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO
[9]
2-4
[10]
Bai L, 2002, INT J ONCOL, V21, P685